Journal article
GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes
Abstract
Whether glucagon-like peptide-1 receptor agonists (GLP1-RA) reduce detrimental kidney outcomes is uncertain. In secondary analyses, trials have shown consistent reductions in macroalbuminuria, but inconclusive results about kidney function decline. To help clarify this, we conducted a cohort study to compare kidney and cardiovascular outcomes in individuals who started GLP1-RA or dipeptidyl peptidase-4 inhibitors (DPP4i) (reduces degradation of …
Authors
Xu Y; Fu EL; Clase CM; Mazhar F; Jardine MJ; Carrero JJ
Journal
Kidney International, Vol. 101, No. 2, pp. 360–368
Publisher
Elsevier
Publication Date
February 2022
DOI
10.1016/j.kint.2021.10.033
ISSN
0085-2538